Key Takeaways
1. New psychiatric treatments are expanding options but require real-world context. Emerging therapies—such as sublingual dexmedetomidine, lumateperone, and xanomeline-trospium—offer novel mechanisms, improved tolerability, and alternative administration routes. However, clinicians are still determining where these agents fit in practice, making shared clinical experience and practical insights critical for informed use.
2. Innovative research is reshaping how clinicians think about psychiatric and substance use treatment. GLP-1 receptor agonists are gaining attention for substance use disorders, with early evidence suggesting they may reduce addictive behaviors by acting on reward pathways. While still investigational, this highlights a broader shift toward targeting underlying neurobiology rather than just symptoms.
3. Pharmacists play a central role in navigating evolving care models and improving patient outcomes. From optimizing clozapine monitoring after REMS changes to implementing long-acting injectable antipsychotics, pharmacists are key in balancing safety, access, adherence, and education. Their involvement is essential as treatment options become more complex and patient-centered.
